FDA approves Takeda, Protagonist drug for rare blood disorder
The FDA approved rusfertide, a new drug from Takeda and Protagonist Therapeutics to treat a rare blood disease. Rusfertide, which will be branded as Mimrylo, can now be prescribed for polycythemia vera, a disease in ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.